Content area

|
|

Isoflavoner som behandlingsmulighed ved østrogenmangel

Forfatter(e)

Max Norman Tandrup Lambert1, Sven Tyge Langkjer2 & Per Bendix Jeppesen1

1) Institut for Klinisk Medicin, Diabetes og Hormonsygdomme, Health, Aarhus Universitet, 2) Kræftafdelingen, Aarhus Universitetshospital

Ugeskr Læger 2020;182:V11190643

Reference: 
Ugeskr Læger 2020;182:V11190643
Isoflavones have therapeutic efficacy inoestrogen deficiency

Max Norman Tandrup Lambert, Sven Tyge Langkjer & Per Bendix Jeppesen:

Ugeskr Læger 2020;182:V11190643

In this review, we discuss isoflavones, which are bioactive selective estrogen receptor modulators shown to have therapeutic efficacy in reducing bone resorption and improving menopause symptoms in women with estrogen deficiency. The European Food Safety Authority reached consensus that there “is no evidence of harm” of isoflavone supplements for peri- and post-menopausal women. Bioavailable isoflavone aglycones being rich in fermented sources are shown to have enhanced effects compared to glycosides, and isoflavones represent an effective and safe new treatment for oestrogen deficient bone loss and climacteric symptoms.>

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Julius Vindbjerg Nissen | 14/08
1 Kommentar
af Ulrich Fredberg | 14/08
1 Kommentar
af Karen Flink Konstantin-Hansen | 13/08
3 kommentarer
af Susanne Mejlby Nielsen | 06/08
4 kommentarer
af Gunvor Kramshøj Larsen | 04/08
28 kommentarer
af Olaf Bjarne Paulson | 03/08
1 Kommentar
af Hanne Hulgaard | 02/08
4 kommentarer
af Christian Stefan Legind | 28/07
1 Kommentar
af Connie Lærkholm Hansen | 23/07
1 Kommentar